Generic Namenda XR Availability
See also: Generic Namenda
NAMENDA XR (memantine hydrochloride - capsule, extended release; oral)
Has a generic version of Namenda XR been approved?
No. There is currently no therapeutically equivalent version of Namenda XR available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Namenda XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Adamantane derivatives in the prevention and treatment of cerebral ischemia
Issued: October 29, 1991
Inventor(s): Bormann; Joachim & Gold; Markus R. & Schatton; Wolfgang
Assignee(s): Merz + Co. GmbH & Co.
A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.Patent expiration dates:
- April 11, 2015✓
- April 11, 2015
Modified release formulations of memantine oral dosage forms
Issued: October 18, 2011
Inventor(s): Rastogi; Suneel K. & Rao; Niranjan & Periclou; Antonia & Abramowitz; Wattanaporn & Dedhiya; Mahendra G. & Mahashabde; Shashank
Assignee(s): Forest Laboratories Holdings Limited
The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Patent expiration dates:
- March 24, 2029✓
- March 24, 2029
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- June 21, 2013 - NEW DOSAGE FORM
- Namenda XR Advanced Consumer Information (Micromedex)
- Memantine Consumer Information (Wolters Kluwer)
- Memantine solution Consumer Information (Wolters Kluwer)
- Memantine tablets Consumer Information (Wolters Kluwer)
- Memantine Consumer Information (Cerner Multum)
- Memantine Advanced Consumer Information (Micromedex)
- Memantine Hydrochloride AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|